


Novel interaction mechanism of a domain antibody based inhibitor of human vascular endothelial growth factor with greater potency than ranibizumab and bevacizumab and improved capacity over aflibercept.

Adam Walker¹, Chun-wa Chung², Margaret Neu², Manish Burman¹, Thil Batuwangala¹, Gavin Jones¹, Chi-Man Tang^{1*}, Michael Steward¹, Michael Mullin³, Nadia Tournier³, Alan Lewis³, Justyna Korczynska^{1,3}, Vicky Chung⁴, Ian Catchpole^{1#}

SUPPLEMENTAL DATA.

SI Figure 1: Sample electron density maps of the V_k dAb/VEGF-107 interaction, (A) V_k dAb L chain and (B) M chain and V_H dAb/VEGF-107 complexes, (C) V_H dAb L chain and (D) M chain.



SI Table 1: Statistics for Xray data collection and refinement

(collection on a single crystal)	V_K dAb: VEGF	V_H dAb: VEGF
Data collection *		
Space group	I222	C2
Cell dimensions		
a, b, c (Å)	61.22, 147.13, 175.17	107.11, 130.40, 81.18
α, β, γ (°)	90.000, 90.000, 90.000	90.000, 106.53, 90.000
Resolution (Å)	73.56-2.70 (2.85-2.70)	51.34-3.45 (3.64-3.45)
R_{merge}	0.088 (0.482)	0.0112 (0.439)
$I/\sigma I$	18.5 (3.8)	7.8 (2.7)
Completeness (%)	99.5 (100.0)	99.4 (99.9)
Redundancy	6.6 (6.8)	3.8 (3.7)
Refinement		
Resolution (Å)	73.56 -2.70	51.34 -3.45
No. reflections	145182 (21768)	52467 (7842)
No. uniq reflections	22056 (3181)	14048 (2066)
$R_{\text{work}}/ R_{\text{free}}$	0.205/0.261	0.214/0.262
No. atoms	3329	5024
Protein	3256	5024
Ligand/ion	0/0	0/0
Water	73	0
B-factors		
Protein	74.625	110.313
Ligand/ion	0/0	0/0
Water	63.849	/
R.m.s deviations		
Bond lengths (Å)	0.007	0.004
Bond angles (°)	1.202	0.967
Ramachandran plot #		
Most favoured regions [%]	91	88.3
Additional allowed regions	9	11.7
Generously allowed regions	0	0
Disallowed regions [%]	0	0

- Highest resolution shell is shown in parenthesis

Calculated by Procheck